Tumor protein 53 gene mutations without 17p13 deletion have no significant clinical implications in chronic lymphocytic leukemia. Detection of a new mutation

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:3087085 15 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
Tumor protein 53 gene mutations without 17p13 deletion have no significant clinical implications in chronic lymphocytic leukemia. Detection of a new mutation
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: The tumor protein p53 (TP53) gene may be inactivated through 17p13 deletion, somatic mutations, or both. In chronic lymphocytic leukemia (CLL) although 17p13 deletion is correlated with poor prognosis, the role of sole TP53 mutations remains controversial. Materials and Methods: We carried out a mutation analysis of TP53 gene in 72 patients with CLL. Results: Seventy-one (98.6%) patients carried the polymorphic site c.215C>G, p.Pro72Arg, but its presence was not correlated with overall survival (OS). Moreover, 19 (26.4%) patients carried a mutation of TP53. Among the eight detected mutations, to our knowledge, one (c.587G>A) has never been reported in the past. There was a correlation of the mutation burden with the stage of the disease (p=0.022), but not with OS. None of the detected mutations was individually correlated with OS. Conclusion. The clinical significance of TP53 mutations is still a matter of debate and larger studies and meta-analyses are required to reach an unequivocal conclusion.
Έτος δημοσίευσης:
2017
Συγγραφείς:
Diamantopoulos, P.T.
Samara, S.
Kollia, P.
Giannakopoulou, N.
Sofotasiou, M.
Kalala, F.
Kodandreopoulou, E.
Zervakis, P.
Vassilakopoulos, T.
Siakantaris, M.
Mantzourani, M.
Angelopoulou, M.
Kyrtshonis, M.-C.
Korkolopoulou, P.
Patsouris, E.
Viniou, N.-A.
Περιοδικό:
ANTICANCER RESEARCH
Εκδότης:
International Institute of Anticancer Research
Τόμος:
37
Αριθμός / τεύχος:
5
Σελίδες:
2387-2391
Λέξεις-κλειδιά:
beta 2 microglobulin; hemoglobin; lactate dehydrogenase; protein p53; protein p53; TP53 protein, human, adult; aged; Article; cancer prognosis; cancer staging; cancer survival; chromosome 17p; chromosome deletion; chronic lymphatic leukemia; female; fluorescence in situ hybridization; follow up; gene mutation; hemoglobin blood level; homozygosity; human; major clinical study; male; overall survival; peripheral lymphocyte; priority journal; thrombocyte count; very elderly; chromosome 17; chromosome deletion; chronic lymphatic leukemia; genetics; middle aged; mutation, Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 17; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Tumor Suppressor Protein p53
Επίσημο URL (Εκδότης):
DOI:
10.21873/anticanres.11577
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.